$0.00
$2.25
bear $0.00
base $0.00
bull $2.25
margin of safety $1.00
market price* $17.63
Business condition attached to the margin of safety
At least four consecutive quarters (trailing twelve months) of positive cash generation after deducting stock-based compensation, working-capital swings and maintenance capital spending, at roughly $10 million a year or better.
Omada Health sells virtual chronic-care programs (diabetes, prediabetes, hypertension, musculoskeletal and weight-health programs, including a GLP-1 support track) to health plans, pharmacy benefit managers, employers and health systems. It ended 2025 with more than 2,000 customers and over 886,000 enrolled members. Revenue grew from $122.8 million in 2023 to $169.8 million in 2024 and $260.2 million in 2025, and was $165.9 million in the first half of 2026 versus $116.3 million a year earlier. It went public in June 2025 and used part of the proceeds to repay its $31 million term loan. What the business earns for its owners. We measure this as operating cash flow, less the swings in working capital, less stock-based compensation (a real cost, since it pays staff with shares), less the capital spending needed just to stay in place. On that basis Omada has not yet produced a profit for owners: about -$60 million in 2023, -$40 million in 2024 and roughly -$2 million in 2025. The improvement is large, but 2025 was still slightly negative, and stock compensation of $13.0 million in 2025 absorbed all of the $14.5 million of cash flow left after working capital. In the first half of 2026 operating cash flow was still negative (-$7.8 million, better than -$13.3 million a year earlier), while net income turned positive ($2.3 million for the half, driven by $5.3 million in the second quarter after a $3.0 million loss in the first). One profitable quarter is not enough to move the earnings level, so the starting point remains about zero. Growth-path check. Owner earnings improved by about $37.6 million from 2024 to 2025 but remain below zero, so there is no positive base to grow. The base case therefore starts at zero rather than at a positive figure. Bear case ($0 per share). Omada's sales are highly concentrated: its top five health plan and PBM partners were 77% of 2025 revenue, and two affiliates of The Cigna Group alone were 32% and 33%. The filing states that customers and channel partners work with Omada on a non-exclusive basis and that most contracts can be ended for convenience on notice. If a major partner shifts volume elsewhere, the business does not reach positive owner earnings, and we assign no value. The company appears to have no debt after the 2025 repayment, so the case bottoms at zero rather than below it. Base case ($0 per share). Nothing we can name and evidence today produces positive owner earnings after stock compensation. Revenue growth of 53% in 2025 and about 43% in the first half of 2026 is real, but it depends on the digital-care market expanding and on winning more members, which is not secured by contract, so we do not credit it. Margin expansion, the newly announced ability to prescribe GLP-1 medications, and further leverage on fixed costs are likewise left out because none has yet produced sustained positive owner earnings. Bull case ($2.25 per share). This assumes the operating leverage already visible keeps working: from 2024 to 2025, owner earnings improved by roughly $0.42 for every additional revenue dollar, and the first half of 2026 already shows revenue running about 43% above the prior year. We assume owner earnings settle at about $15 million a year, roughly what the first-half 2026 profit improvement implies once stock compensation (about $10 million in the half) is absorbed, and last 15 years with no further growth, then nothing. That is about $146 million today, spread over roughly 64 million shares. We stop at 15 years because contracts are terminable and concentrated, so we can name no mechanism that carries earnings beyond that. Per-share caveat. Reported average share counts for 2023 and 2024 (7.1 and 7.7 million) reflect only common shares outstanding before the IPO, when preferred stock had not yet converted; so historical per-share figures are larger in magnitude than the economics imply. Values above use about 64 million shares outstanding after the IPO. What would make this wrong. If cash generation after stock compensation becomes clearly positive over the next several quarters, the base case would rise well above zero. If the Cigna-affiliated relationships weaken, even the bull case falls. The margin-of-safety price applies only once the business shows sustained positive cash generation of roughly $10 million a year or more after stock compensation.